Fig. 3

The impact of the TME contexture in patient response to ONCOFID-P-B™. a-g Characterization of the immune infiltrate in bladder CIS collected after the intensive phase in patients achieving or not a CR after the intensive phase. h-k Characterization of the immune infiltrate in bladder CIS collected at baseline in patients achieving or not a CR at the end of the 15-month study. Significantly different data are represented by *p < 0.05, **p < 0.01. Floating box extends from 25th to 75th percentiles, line through the box indicates median, and bars extend from the smallest to largest values. l-p Kaplan-Meier survival curves for disease-free survival according to the immune cell composition and cell-to-cell interactions at baseline in ONCOFID-B-P™-treated bladder CIS patients. The median cut-off of each immune variable was used to separate high and low infiltrated groups. Log-rank p values, hazard ratios (HR) and 95% confidence intervals (CI) are reported in each graph